Deals, Partnering

Pfizer and Debiopharm collaborate to co-develop Tremelimumab in advanced melanoma

Posted on 07 January 2010

Tags: ,

A co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab. Debiopharm will assume responsibility for conducting the phase 3 trial of tremelimumab and Pfizer will retain responsibility for worldwide commercialization of the compound.

Print Friendly, PDF & Email

Leave a Reply